Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial [0.03%]
替宁替尼治疗晚期或转移性胆管癌成人患者的疗效：一项多中心、开放标签的II期试验
Milind Javle,Christos Fountzilas,Chih-Yi Liao et al.
Milind Javle et al.
Background: Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired ...
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials [0.03%]
一项在先前接受过治疗的局部晚期或转移性KRASG12C突变型结直肠癌患者中开展的有关glecirasib单药或联合西妥昔单抗治疗疗效的研究（JAB-21822-1002和JAB-21822-1007）：两项开放标签非随机对照Ⅰ/Ⅱ期试验
Jian Li,Zhenghang Wang,Jing Huang et al.
Jian Li et al.
Background: KRASG12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been identified as a primary mech...
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial [0.03%]
中国肝内胆管癌术后患者中卡瑞利珠单抗联合卡培他滨辅助治疗的有效性和安全性：一项在中国开展的单臂、单中心、开放性II期临床试验（ACC研究）
Zheng Wang,Lixing Li,Peiran Huang et al.
Zheng Wang et al.
Background: Patients with intrahepatic cholangiocarcinoma have a poor prognosis and high postoperative recurrence rates. Immunochemotherapy has been approved as a first-line treatment for advanced biliary tract cancer. We...
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis [0.03%]
代谢功能紊乱相关steatoohepatitis的当前和新兴治疗格局
Wenhao Li,William Alazawi,Rohit Loomba
Wenhao Li
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an estimated increase in prevalence of more than 50...
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease [0.03%]
弥合中东和北非炎症性肠病临床试验中的代表性差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin et al.
Mohammad Shebab et al.
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
Stephanie A Vuijk
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial [0.03%]
mirikizumab治疗中至重度活动性溃疡性结肠炎儿科患者的有效性和安全性（SHINE-1）：一项多中心、开放标签、非随机Ⅱ期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner et al.
Jess L Kaplan et al.
Background: Mirikizumab, a humanised immunoglobulin G4 monoclonal antibody, targets the p19 subunit of IL-23, with demonstrated efficacy and safety in adults with ulcerative colitis and Crohn's disease. This study evaluat...
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity [0.03%]
呼吁对LGBTQIA+人群进行结直肠癌筛查以实现平等权益
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky et al.
Vidhi Singh et al.
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care [0.03%]
炎性肠病基本药物目录：是时候提高全球治疗标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein et al.
Nanne K de Boer et al.